BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 6.3%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares fell 6.3% during mid-day trading on Friday . The company traded as low as $4.77 and last traded at $4.78. 1,389,096 shares traded hands during mid-day trading, a decline of 57% from the average session volume of 3,262,208 shares. The stock had previously closed at $5.10.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $13.29.

BioCryst Pharmaceuticals Trading Down 6.5 %

The company’s 50-day moving average price is $5.29 and its two-hundred day moving average price is $5.68. The company has a market cap of $983.34 million, a P/E ratio of -4.04 and a beta of 1.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The firm had revenue of $93.40 million for the quarter, compared to the consensus estimate of $89.19 million. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.62 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Los Angeles Capital Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 68.0% during the 1st quarter. Los Angeles Capital Management LLC now owns 89,614 shares of the biotechnology company’s stock valued at $455,000 after purchasing an additional 36,284 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 15.4% during the 4th quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after purchasing an additional 2,371,401 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 15.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,774,754 shares of the biotechnology company’s stock valued at $10,631,000 after purchasing an additional 232,043 shares in the last quarter. Counterweight Ventures LLC bought a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $81,000. Finally, Quarry LP purchased a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at about $54,000. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.